Resources for Dengue Diagnostics

In 128 countries, 400 million people are infected each year and over half the world’s population is at risk of infection with Dengue viruses.

As a leading discoverer, developer, and manufacturer of tropical disease IVDs, CTK is proud to offer a complete line of products for the management of dengue infection:

  • Rapid Test: For all market
  • ELISA Kit: To confirm rapid test results High- throughput testing

What makes CTK’s dengue product range unique?

  • The Dengue IgG and IgM Rapid Test and ELISA kit are IgGand IgM-specific capture immunoassays that use recombinant dengue virus antigen developed with the latest technology as patented by the U.S. Center for Disease Control (U.S. CDC).
  • The Dengue Ag Rapid Test and ELISA kit use the affinity purified pan NS1 polyclonal antibody paired with multiple monoclonal antibodies that ensures NS1 detection for all four dengue serotypes as well as isolates. Nature Reviews Rheumatology 10, 494–501 (2014)
  • The IgG and IgM antibody and NS1 antigen controls are developed with cutting-edge recombinant antibody and antigen technologies, produced by mammalian cells. Their supply is unlimited, and they can be transported to any country without being subjected to biohazardous regulations.
  • Recombinant E-protein, recombinant NS1 protein, and Pan NS1 polyclonal and monoclonal antibody are manufactured at our State-of-the-Art facility, located in the biotech hub of San Diego, California. These premium reagents are useful for the dengue research community, and are cited in many research publications.

Worldwide Health Concerns: Dengue and Zika virus

On February 1, 2016, the World Health Organization (WHO) declared a Public Health Emergency in regards to Zika virus infection following the rapid increase of microencephaly cases in newborn babies whose mothers had an infection history of the Zika virus during pregnancy.

Dengue and Zika viruses are both members of the flavivirus family, transmitted by the same Aedes mosquitoes, and share many clinical symptoms. The cross-reactivity of antibodies between Zika and dengue is very common, making detection difficult and complicated. The first step in the Pan American Health Organization algorithm for the detection of Zika virus is to confirm the status of Dengue infection.